Table 1 Patients’ characteristics according to FFAR4 status
From: Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer
Characteristics | All patients | Hormone receptor-positive patients | ||||||
|---|---|---|---|---|---|---|---|---|
Total (n = 307) (%) | FFAR4 Low (n = 158) (%) | FFAR4 High (n = 149) (%) | P | Total (n = 212) (%) | FFAR4 Low (n = 99) (%) | FFAR4 High (n = 113) (%) | P | |
Age at diagnosis | Â | Â | Â | 0.915 | Â | Â | Â | 0.753 |
  ≤ 35 | 10 (3) | 6 (60) | 4 (40) |  | 10 (5) | 6 (60) | 4 (40) |  |
 36–50 | 116 (38) | 60 (52) | 56 (48) |  | 82 (39) | 40 (49) | 42 (51) |  |
 51–64 | 123 (40) | 64 (52) | 59 (48) |  | 74 (35) | 32 (43) | 42 (57) |  |
  ≥ 65 | 58 (19) | 28 (48) | 30 (52) |  | 46 (21) | 21 (46) | 25 (54) |  |
Menstrual status | Â | Â | Â | 0.909 | Â | Â | Â | 0.383 |
 Premenopausal | 131 (43) | 68 (52) | 63 (48) |  | 93 (44) | 45 (48) | 48 (52) |  |
 Postmenopausal | 176 (57) | 90 (51) | 86 (49) |  | 119 (56) | 54 (45) | 65 (55) |  |
AJCC stage | Â | Â | 0.989 | Â | Â | Â | Â | 0.837 |
 I | 85 (28) | 43 (50) | 42 (50) |  | 64 (30) | 30 (47) | 34 (53) |  |
 II | 140 (45) | 73 (52) | 67 (48) |  | 94 (44) | 42 (45) | 52 (55) |  |
 III | 82 (27) | 42 (51) | 40 (49) |  | 54 (26) | 27 (50) | 27 (50) |  |
Histology | Â | Â | Â | 0.694 | Â | Â | 0.915 | |
 Ductal | 270 (88) | 139 (51) | 131 (49) |  | 182 (86) | 84 (46) | 98 (54) |  |
 Lobular | 15 (5) | 9 (60) | 6 (40) |  | 13 (6) | 7 (54) | 6 (46) |  |
 Other | 22 (7) | 10 (45) | 12 (55) |  | 17 (8) | 8 (47) | 9 (53) |  |
Grade | Â | Â | Â | 0.199 | Â | Â | Â | 0.087 |
 1 or 2 | 187 (61) | 102 (55) | 85 (45) |  | 137 (65) | 70 (51) | 67 (49) |  |
 3 | 120 (39) | 56 (47) | 64 (53) |  | 75 (35) | 29 (39) | 46 (61) |  |
Tumor size, cm | Â | Â | Â | 0.416 | Â | Â | Â | 0.890 |
  ≤ 2 | 124 (40) | 60 (48) | 64 (52) |  | 94 (44) | 43 (46) | 51 (54) |  |
  > 2 | 183 (60) | 98 (54) | 85 (46) |  | 118 (56) | 56 (47) | 62 (53) |  |
Lymph node status | Â | Â | Â | 0.909 | Â | Â | Â | 0.491 |
 Positive | 142 (46) | 74 (52) | 68 (48) |  | 95 (45) | 47 (50) | 48 (50) |  |
 Negative | 165 (54) | 84 (51) | 81 (49) |  | 117 (55) | 52 (44) | 65 (56) |  |
ER | Â | Â | Â | 0.023* | Â | Â | Â | 1.000 |
 Positive | 198 (64) | 92 (46) | 106 (54) |  | 198 (93) | 92 (46) | 106 (54) |  |
 Negative | 109 (36) | 66 (61) | 43 (39) |  | 14 (7) | 7 (50) | 7 (50) |  |
PR | Â | Â | Â | 0.250 | Â | Â | Â | 0.267 |
 Positive | 177 (58) | 86 (49) | 91 (51) |  | 177 (83) | 86 (49) | 91 (51) |  |
 Negative | 130 (42) | 72 (55) | 58 (45) |  | 35 (17) | 13 (37) | 22 (63) |  |
HER | Â | Â | Â | 0.901 | Â | Â | Â | 1.000 |
 Positive | 92 (30) | 48 (52) | 44 (48) |  | 51 (24) | 24 (47) | 27 (53) |  |
 Negative | 215 (70) | 110 (51) | 105 (49) |  | 161 (76) | 75 (47) | 86 (53) |  |
Ki-67 | Â | Â | Â | 0.171 | Â | Â | Â | 0.008* |
  ≤ 20% | 157 (51) | 87 (55) | 70 (45) |  | 123 (58) | 67 (54) | 56 (46) |  |
  > 20% | 150 (49) | 71 (47) | 79 (53) |  | 89 (42) | 32 (36) | 57 (64) |  |
Molecular subtype | Â | Â | Â | 0.066 | Â | Â | Â | 0.279 |
 Luminal A | 75 (24) | 40 (53) | 35 (47) |  | 75 (35) | 40 (53) | 35 (47) |  |
 Luminal B HER2- | 86 (28) | 35 (41) | 51 (59) |  | 86 (41) | 35 (41) | 51 (59) |  |
 Luminal B HER2+ | 51 (17) | 24 (47) | 27 (53) |  | 51 (24) | 24 (47) | 27 (53) |  |
 HER2 non-luminal | 41 (13) | 25 (61) | 16 (39) |  |  |  |  |  |
Hormone receptor | Â | Â | Â | 0.014* | Â | Â | Â | Â |
 Positive | 212 (69) | 99 (47) | 113 (53) |  |  |  |  |  |
 Negative | 95 (31) | 59 (62) | 36 (38) |  |  |  |  |  |